COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pilot Study for First Clinical Use of sc2Wear Furosemide Combination Product

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02804035
Recruitment Status : Completed
First Posted : June 17, 2016
Last Update Posted : October 16, 2017
Information provided by (Responsible Party):
scPharmaceuticals, Inc.

Brief Summary:

The proposed pilot study aims to gain experience with the first clinical use of the to-be marketed drug-device combination product, the sc2Wear Furosemide Combination Product and to assess methods and procedures for evaluation of product performance.

The objectives of this study are:

  • To gain first in man experience of a novel drug-device combination product
  • To evaluate the suitability of the methods and procedures for evaluating of the performance of the sc2Wear Pump

Condition or disease Intervention/treatment Phase
Heart Failure Combination Product: sc2Wear Furosemide Phase 2

Detailed Description:

This study will be an open label, single-dose study to gain experience with first clinical use and to evaluate the suitability of the methods and procedures for evaluation of product performance of a to-be-marketed drug-device combination product (sc2WearTM Furosemide Combination Product) in a minimum of 20 adult male and female subjects previously diagnosed with mild to advanced heart failure (NYHA class II-IV). The study will enroll up to 30 Subjects to ensure a minimum of 20 evaluable Subjects. Methodology: Each Subject will complete Screening, Treatment, and Follow-Up Phases on an outpatient basis. During the Screening Phase, all Subjects who sign the informed consent form and satisfy the inclusion/exclusion criteria will be enrolled into the trial. Drug administration may start on the day of enrollment or be scheduled within 3 days of completion of Screening procedures. However, if the treatment visit doesn't occur within 3 days of initial screening, subjects may be rescreened and treated within 3 days of rescreening. The Treatment Phase comprises a preprogrammed bi-phasic 5 hour drug administration. Treatment Day observations will commence with pre-placement procedures and continue until one hour after device removal. Device preparation, placement and removal will be performed by study staff in accordance with product instructions for use. Removal will occur within

3 hours of completion of drug delivery (8 hours of start of administration). Subjects will return 5-7 days after the Treatment Day for a post treatment follow-up and photography. After preparation of the skin, the device will be placed on the upper abdominal area by clinical study staff. Subjects are advised to avoid strenuous physical activity or activities that could expose the device to moisture such as swimming, bathing or showering. Participants will be informed that marked diuresis may ensue after activation, and that they should avoid travel, operating a vehicle or other situations without immediate access to bathroom facilities. For each Subject, a reusable components (Activator) and a single-use unit (Cartridge) will be used. Following removal from the skin, the assembled device will be inspected and photographed by the site staff. The used device (assembled Cartridge and Activator) will be placed in a sealed container and returned for further inspection and measurement of residual volume in the device reservoir.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label First in Human Use Pilot Study of a To-Be-Marketed Drug-Device Combination Product (sc2Wear Furosemide Combination Product) in Subjects With Chronic Heart Failure
Study Start Date : July 2016
Actual Primary Completion Date : August 2016
Actual Study Completion Date : August 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
Drug Information available for: Furosemide

Arm Intervention/treatment
Experimental: sc2Wear Furosemide Combination Product
Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
Combination Product: sc2Wear Furosemide
Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)

Primary Outcome Measures :
  1. Absence of Major Product Failure [ Time Frame: 1-5 hours ]
    Freedom from failures leading to infusion errors.

Secondary Outcome Measures :
  1. Local Pain Tolerance [ Time Frame: 1-5 hours ]
    Subject-reported pain using 11 point numeric rating scale of 0 to 10.

  2. Local Skin Tolerance [ Time Frame: 1-8 days ]
    Adhesive site skin inspection for erythema, edema and other local reactions using 8 point scale.

  3. Incidence of treatment-emergent Adverse Events and Serious Adverse Events [ Time Frame: 1-8 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities.
  2. Male and female Subjects ≥18 years of age
  3. New York Heart Association (NYHA) Class II-IV Heart Failure.
  4. In the opinion of the Investigator, able to participate in the study.
  5. If Subject is on oral diuretic, willing to suspend the oral furosemide or other loop diuretic treatment on the day of treatment (use of oral diuretic within 8 hours of start of treatment is not recommended)
  6. If Subject has significant body hair on the abdomen, willing to clip or shave the area where the device will be placed prior to treatment.
  7. Has the ability to understand the requirements of the study, and is willing to comply with all study procedures.

Exclusion Criteria:

  1. Contraindication to furosemide.
  2. History of chronic skin conditions requiring medical therapy.
  3. Skin reaction to medical adhesives or history of poor skin adherence of adhesives.
  4. Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema, etc.
  5. Diabetic patients currently using an insulin pump and/or interstitial glucose monitors.
  6. Clinically significant abnormalities at Screening in safety laboratory tests.
  7. Hypokalemia - Potassium of < 3.6 mmol/L.
  8. Systolic BP (SBP) < 90 mm Hg.
  9. Temperature > 38°C (oral or equivalent) or sepsis or active infection requiring IV anti-microbial treatment.
  10. History of major abdominal surgery affecting the site of device placement.
  11. Participation in another trial, within 30 days prior to Screening.
  12. History of hepatitis B, hepatitis C, or HIV
  13. History of current or recent alcohol abuse.
  14. Female subject who is pregnant or lactating.
  15. Any surgical or medical condition that in the opinion of the Investigator may interfere with participation in the study or that may affect the outcome of the study.
Layout table for additonal information
Responsible Party: scPharmaceuticals, Inc. Identifier: NCT02804035    
Other Study ID Numbers: CP-00002
First Posted: June 17, 2016    Key Record Dates
Last Update Posted: October 16, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action